Novacyt Stock

Novacyt Equity Ratio

The Equity Ratio of Novacyt (ALNOV.PA) as of Sep 16, 2026 is 67.79 %. In the previous year, Equity Ratio was 65.20 % — a change of 3.98% (higher).

Equity Ratio

67.79 %

YoY

3.98%

Last updated:

Equity Ratio of Novacyt is 2026 67.79 % . Equity Ratio of Novacyt was 2025 65.20 % . It decreases by 3.98% higher compared to the previous year.

The Novacyt Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2017
73.22 GBP
Jan 1, 2018
61.94 GBP
Jan 1, 2019
46.98 GBP
Jan 1, 2020
64.33 GBP
Jan 1, 2021
77.20 GBP
Jan 1, 2022
81.77 GBP
Jan 1, 2023
65.20 GBP
Jan 1, 2024
67.79 GBP
The Novacyt Equity Ratio history
YEAREquity RatioYoY
67.79 %+3.98%
65.20 %-20.27%
81.77 %+5.92%
77.20 %+20.01%
64.33 %+36.94%
46.98 %-24.15%
61.94 %-15.41%
73.22 %+25.45%
58.37 %-5.12%
61.52 %-19.13%
76.08 %
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Equity Ratio of Novacyt is 67.79 % in 2026.

Equity Ratio of Novacyt changed from 65.20 % to 67.79 %, representing a 3.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Novacyt since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Novacyt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Novacyt

All Key Metrics — Novacyt